HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00269919

Long-term injectable risperidone for schizophrenia or schizoaffective disorder

About this titleRead the official source — NCT00269919

Researchers studied Risperidone Long-Acting Injectable (RLAI) to find out how it affected psychotic symptoms in people with schizophrenia.

Medication studyAges 18–65South Korea
The study in practice

Understand this study

What did researchers investigate?

Researchers studied Risperidone Long-Acting Injectable (RLAI) to find out how it affected psychotic symptoms in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
SeoulSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2005
Recruitment status
Completed
Enrollment listed in the registry
40
Sponsor
Janssen Korea, Ltd., Korea
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
South Korea
Age range
From 18 Years to 65 Years
Official registry ID
NCT00269919
Official title
Show the full official title

Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Seoul

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

Researchers studied Risperidone Long-Acting Injectable (RLAI) to find out how it affected psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Janssen Korea, Ltd., Korea.

Did this study involve medication?

Yes. The study involved medication, including Risperidone Long-Acting Injectable (RLAI).

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies